BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 Mainz Biomed NV , a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities. | April 27, 2023
Since the end of 2021, we have been keeping a promise to the future: we are supplying a greentec steel Edition of all the flat steel products manufactured at our Linz site. The steel produced. | April 12, 2023
Issuer: Mainz BioMed N.V. / Key word(s): Annual Results Mainz Biomed Provides Full Year 2022 Financial Results 10.04.2023 / 09:01 CET/CEST The issuer is solely responsible for the
Issuer: Mainz BioMed N.V. / Key word: Miscellaneous
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
04.04.2023 /. | April 4, 2023
Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effectiveTwo mRNA biomarkers found to be particularly valuable in detecting disease signals in advanced. | March 29, 2023